Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
An opioid agonist is a drug that binds to and activates one or more opioid receptors. Activation of mu opioid receptors can reduce pain and produce sedation, euphoria, slowed breathing, and other effects. Full agonists can produce a strong receptor response, while partial agonists activate the receptor to a more limited degree. Examples include morphine, oxycodone, fentanyl, methadone, and the partial agonist buprenorphine.
read more about opioid agonist ...Opioid agonists are used for selected cases of moderate to severe pain, anesthesia, and palliative symptom control. Methadone and buprenorphine are also used to treat opioid use disorder by reducing withdrawal symptoms and cravings. Some opioids have specialized uses for cough or diarrhea. The expected benefit must be weighed against respiratory, dependence, interaction, and overdose risks.
Opioid agonists activate receptors in the brain, spinal cord, gastrointestinal tract, and other tissues. Mu receptor activation reduces transmission and perception of pain but also suppresses respiratory drive. It slows gastrointestinal movement and can affect reward pathways involved in reinforcement and dependence. The effect depends on receptor activity, dose, route, tolerance, and use of other central nervous system depressants.
Full agonists can produce progressively greater receptor effects as the dose increases until other limits are reached. Morphine, fentanyl, oxycodone, and methadone are full mu opioid agonists. Buprenorphine is a partial mu agonist with high receptor affinity and a ceiling on some opioid effects, particularly respiratory depression. Partial agonists can still cause dependence, sedation, and overdose, especially when combined with other depressants.
Common effects include constipation, nausea, itching, sleepiness, dizziness, and difficulty urinating. Serious risks include respiratory depression, overdose, physical dependence, withdrawal, opioid use disorder, and dangerous interactions with alcohol, benzodiazepines, or other sedatives. Tolerance to some effects can develop with repeated use, but protection from overdose is incomplete. Slow or stopped breathing, blue or gray skin, pinpoint pupils, or inability to wake requires emergency response and naloxone when available.
Yes. Buprenorphine is a partial agonist at the mu opioid receptor. It activates the receptor less fully than agents such as methadone or morphine.
Yes. Methadone is a long-acting full mu opioid agonist used for pain and opioid use disorder under specific treatment requirements.
Yes. Repeated exposure can lead to physiological adaptation and withdrawal when the medicine is stopped abruptly. Physical dependence is not identical to opioid use disorder.
Naloxone is an opioid antagonist that can temporarily reverse opioid-induced respiratory depression. Emergency medical care is still necessary because its effect can wear off before the opioid does.
Chapter 3A: Overview of Medications for Opioid Use Disorder. Substance Abuse and Mental Health Services Administration (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK574908/. Date Accessed August 6, 2026.
Opioid Analgesics. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK459161/. Date Accessed August 6, 2026.
Morphine Sulfate Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3c847554-3b4b-4d24-a145-2ef7e9b83699&version=13. Date Accessed August 6, 2026.
Buprenorphine. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK459126/. Date Accessed August 6, 2026.
FDA Recommends Health Care Professionals Discuss Naloxone With All Patients When Prescribing Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain. Date Accessed August 6, 2026.